42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel
Results include six complete responses (6/64); twenty-one partial responses (21/64)
Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting
Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025
Company to host virtual KOL event Monday, November 18, 2024; 2:30 PM EST featuring
Dr. Sandra D'Angelo, M.D. (Memorial Sloan Kettering Cancer Center) - register here
CTOS presentation details:
- Title: Planned Analysis of the Pivotal IGNYTE-ESO Trial of Lete-Cel in Patients with Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (Paper 84)
- Session 12: Immunology: Podium presentation
- Presenter: Sandra D'Angelo, MD, Sarcoma Medical Oncologist and Cell Therapist, Memorial Sloan Kettering Cancer Center
- Date/Time: Saturday, November 16, 10:30 AM - 12:00 PM PT / 1:30 - 3:00 PM ET
Adaptimmune virtual KOL event November 18th
Adaptimmune will host a virtual event to discuss and review the IGNYTE-ESO dataset and the impact of engineered cell therapies on the treatment landscape in sarcoma. The event will feature Sandra D'Angelo, M.D., Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center, an investigative clinician in both the SPEARHEAD and IGNYTE-ESO clinical trials, and author and presenter of the IGNYTE-ESO data update at CTOS. A live question and answer session will follow the formal presentation. The virtual event will take place on Monday, November 18, 2024 from 2:30 PM ET to 3:30 PM ET. To register, click here.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.